Acorda and AstraZeneca claim victory over Mylan

The US Court of Appeals for the Federal Circuit has rejected Mylan’s attempt to dismiss two patent lawsuits on the grounds of lack of personal jurisdiction.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Generics

AstraZeneca wins patent infringement case over Farxiga generic

19 October 2021 AstraZeneca has convinced a federal court to uphold challenged claims of a patent related to its diabetes drug Farxiga.

Big Pharma

Mylan fails to void MSD diabetes treatment patent at PTAB

11 May 2021 MSD, known as Merck in the US and Canada, has prevailed against a bid by Mylan Pharmaceuticals and other generic drug makers to invalidate a diabetes treatment patent.

Americas

Allergan launches generic version of AstraZeneca cholesterol tablet

5 May 2016 Pharmaceutical company Allergan has received approval from the US Food and Drug Administration to launch a generic version of a cholesterol drug owned by AstraZeneca.

More features

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation: Follow the money (Part I)

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Barnes & Thornburg reveals five new IP leaders

Former PTAB judge joins Sterne Kessler

GSK escalates mRNA COVID-19 vaccine dispute

Acorda and AstraZeneca claim victory over Mylan

More on this story

Editor's picks

Editor's picks

More features